24/7 Market News Snapshot 07 January, 2025 – SciSparc Ltd. Ordinary Shares (NASDAQ:SPRC)

January 7, 2025

DENVER, Colo., 07 January, 2025 (247marketnews.com) – (Nasdaq:SPRC) are discussed in this article.
SciSparc Ltd. (Nasdaq:SPRC), a forward-looking clinical-stage pharmaceutical company, is experiencing significant momentum in the market, trading at $1.290, representing a remarkable increase of 20.56% from the previous close of $1.070. The surge in the trading volume, reaching approximately 2.91 million shares, indicates heightened investor interest in SciSparc’s prospective ventures.

In a notable expansion of its research and development initiatives, SciSparc has enhanced its collaboration with MitoCareX Bio Ltd. under the guidance of Dr. Alon Silberman. This joint venture has strategically refocused its efforts to include pancreatic cancer, capitalizing on promising in-vitro results that suggest a groundbreaking approach to cancer therapy. MitoCareX is concentrating on the mitochondrial SLC25 protein family, aiming to revolutionize treatment methods through rigorous drug discovery efforts.

The organization employs a cutting-edge computational drug discovery platform that has enabled the screening of millions of small molecules, successfully identifying several candidates with potential anti-cancer properties. Addressing the critical healthcare challenge posed by pancreatic cancer, which currently has a dismal five-year survival rate of only 12%, MitoCareX aims to expand its therapeutic arsenal to improve patient outcomes.

Furthermore, MitoCareX is leveraging advanced artificial intelligence models to navigate extensive chemical landscapes, potentially unveiling new anti-cancer scaffolds targeting the SLC25 protein family. This innovative approach not only broadens the scope of possible treatments but also underscores SciSparc’s commitment to combating serious health challenges through innovative therapies.

As SciSparc continues to focus on its cannabinoid pharmaceuticals while pursuing transformative solutions in cancer treatment, this expansion into pancreatic cancer represents a pivotal milestone in the company’s mission to deliver impactful therapies to those in need.

Related news for (SPRC)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.